Skip to main content


Chronic Lymphocytic Leukemia

Featured

Conference Coverage
Rituximab-abbs may have more economic benefits compared to reference rituximab in patients with NHL, CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic…
News
Study findings highlight substantial economic burden incurred by Medicare among patients with CLL who initiated…
News
A recent study examining ibrutinib combinations in CLL found that ibrutinib plus venetoclax may provide high complete…
News
Study findings suggest the most common reason for novel oral drug discontinuation among patients with CLL in the real-…
News
Findings from a recent study show lower adherence to ibrutinib among patients with CLL in the real-world setting than…
Back to Top